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 2 
Abstract 1 
 2 
Background: Chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 play an important 3 
role in the initial phases of autoimmune thyroiditis (AT); however their serum levels in 4 
patients with Graves’ disease (GD) have never been evaluated in relation to thyroid function 5 
and treatment. 6 
Methods: To evaluate CXCL9 and CXCL11 serum levels in GD, to relate these parameters to 7 
the clinical phenotype, we measured CXCL9 and CXCL11 serum levels in 91 GD patients, 91 8 
AT, 34 non-toxic multinodular goiters (MNG), 31 toxic nodular goiters (TNG) and 91 healthy 9 
controls (age- and sex-matched). 10 
Results: Mean CXCL9, or CXCL11, levels were higher in GD, in comparison with controls, 11 
or euthyroid AT, or MNG, or TNG (*p < 0.05, ANOVA; CXCL9: 274±265, *76±33, 12 
*132±78, *87±48, *112±56 pg/mL; CXCL11: 140±92, *64±20, 108±48, *76±33, *91±41 13 
pg/mL; respectively). Hyperthyroid GD had significantly higher CXCL9 or CXCL11 than 14 
euthyroid or hypothyroid GD. GD with untreated hyperthyroidism had higher CXCL9 or 15 
CXCL11 than hyperthyroid or euthyroid GD under methimazole (MMI) treatment. 16 
Comparable CXCL9 and CXCL11 levels were observed in newly diagnosed untreated 17 
hyperthyroid GD vs. untreated patients with relapse of hyperthyroidism after a previous MMI 18 
course.  19 
Conclusions: Serum CXCL9, and CXCL11, levels are associated with the active phase of GD 20 
both in newly diagnosed and relapsing hyperthyroid patients. The reduction of serum CXCL9 21 
and CXCL11 levels in treated patients with GD may be related to the immunomodulatory 22 
effects of MMI.  23 
24 
 
 
                                                                 
 3 
Introduction 1 
 2 
The impressive complexity of the immune system involved in autoimmune disorders has 3 
been partially clarified in the last years. Briefly, the production of interleukin (IL)-12 4 
promotes the development of T helper (Th)1 cells producing interferon (IFN)-γ, IL-2, and 5 
TNF-α, which activate macrophages and are responsible for cell-mediated immunity and 6 
phagocyte-dependent protective responses. By contrast, the production of IL-4 favors the 7 
development of Th2 cells producing IL-4, IL-5, and IL-13, which are responsible for strong 8 
antibody production, eosinophil activation, and inhibition of several macrophage functions, 9 
thus providing phagocyte-independent protective responses.  10 
Th1 cells tend to produce the proinflammatory responses responsible for killing intracellular 11 
parasites and for perpetuating autoimmune responses, whereas Th2 cells are associated with 12 
the promotion of humoral immunity and of IgE and eosinophilic responses. The production of 13 
transforming growth factor (TGF)-β and IL-6 promotes the development of Th17 cells, a 14 
distinct type of effector T cell that induces tissues damage. Once Th17 cells are established, 15 
IL-23 also participates in their maintenance. Treg cells, which inhibit autoimmunity and 16 
protect against tissue injury, are induced by TGF-β in the absence of IL-6. Thus, TGF-β 17 
functions as a regulator of tissue-damaging Th17 cells when collaborating with IL-6 and as 18 
an activator of anti-inflammatory Treg cells when acting without IL-6 (1). 19 
Chemokines are defined as small (8–15 kDa) proteins that induce chemotaxis and in some 20 
instances, modulate the functional properties of different leucocytes during inflammation. 21 
Chemokines are grouped into four distinct families according to the number and spacing of 22 
two conserved N-terminal cysteine residues. Two chemokine families have multiple 23 
members: the CXC (two N-terminal cysteines separated by a single amino acid) and the CC 24 
(two N-terminal cysteines adjacent) family. The remaining CX3C and the C families each 25 
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contain a single member only, named CX3CL1 (fractalkine) and XCL1 (lymphotactin), 1 
respectively. The CXC chemokines are additionally subdivided into those that contain a 2 
glutamic acid-leucine-arginine (ELR) motif near their N-terminus (e.g. CXCL1 and CXCL8), 3 
and those that do not contain this motif. The non-ELR CXC chemokines can be further 4 
subgrouped based on their structure and target receptor. Three structurally related 5 
chemokines comprise the IFN-inducible non-ELR CXC chemokine subgroup: chemokine C-6 
X-C motif ligand (CXCL)9, CXCL10 and CXCL11 (1-5).  7 
A number of properties distinguish CXCL9, 10 and 11 from the other non-ELR CXC 8 
chemokines and show that these chemokines are closely related. First, these molecules 9 
exhibit significant structural homology being more similar to each other than to any of the 10 
other non-ELR CXC chemokines (2). Second, the genes for these chemokines are all highly 11 
inducible by IFN-γ. Third, all three chemokines share the ability (albeit to varying degrees) to 12 
promote the directional migration of activated and memory, but not naive T cells. Finally, 13 
CXCL9, 10 and 11 all bind to a common receptor named CXCR3. Thus, these chemokines 14 
are considered appropriately as a distinct subfamily (3-5).  15 
Two distinct domains that contributed to CXCR3 internalization were identified. The 16 
carboxyl-terminal domain and beta-arrestin1 were predominantly required by CXCL9 and 17 
CXCL10, and the third intracellular loop was predominantly required by CXCL11 (6).  18 
CXCR3 chemokines play an important role in the initial phases of Graves’ disease (GD) and 19 
autoimmune thyroiditis (AT) (1). 20 
The CXC α chemokines inducible by IFN-γ, CXCL9, CXCL10, CXCL11, are associated 21 
with Th1-mediated immune responses, and among them CXCL10 is a prototype and its 22 
serum levels are increased in several endocrine autoimmune conditions (7-10).  23 
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Recent experimental evidences have demonstrated that CXC chemokines and particularly 1 
CXCL10 play an important physiopathological role in the initial phases of autoimmune 2 
thyroid disorders (AITD) (8, 11, 12).  3 
Expression of CXCL10 and CXCL9 was poor or absent in normal thyroid tissue, while both 4 
the chemokines and their receptor were present in most thyroid glands of patients affected by 5 
GD. CXCL10 and CXCL9 localized to infiltrating lymphocytes and macrophages, as well as 6 
to resident epithelial follicular cells. Of note, maximal expression of CXCL10 and CXCL9 7 
was found in the thyroid gland of patients with recent-onset GD and correlated with IFN-γ (8, 8 
13). At the same time, it was shown that human thyrocytes in primary culture produce large 9 
amounts of CXCL10 when stimulated by IFN-γ (11).  10 
We have previously shown that CXCL10 is associated with the active phase of GD both in 11 
newly diagnosed and relapsing hyperthyroid patients, and that the reduction of circulating 12 
CXCL10 in treated patients with GD may be related to the immunomodulatory effects of 13 
methimazole (MMI) (14, 15).  14 
Increased expression of CXCL10 and CXCL9 was also observed in thyroid tissue specimens 15 
obtained from subjects affected by AT by immunohistochemistry (11), and high levels of 16 
CXCL9 and CXCL11 have been recently shown in patients with AT, in particular in the 17 
presence of hypothyroidism (16-18). Furthermore, we have recently shown that IFN-γ and 18 
TNF-α are able to induce the secretion of the CXCL9 and CXCL11 chemokines in thyrocytes 19 
and fibroblasts of patients with GD and ophthalmopathy (19-21).  20 
Briefly, it has been hypothesized that Th1 cells secreting these chemokines (CXCL9, 10, 11) 21 
were presumably originally attracted to the thyroid gland because of the thyroid autoantigens. 22 
In the thyroid, Th1 cells produce cytokines (such as IFN-γ and TNF-α) that can modulate the 23 
autoimmune response inducing the production of CXCL9, CXCL10 and CXCL11 24 
chemokines not only by lymphocytes, but also from thyrocytes. These chemokines induce the 25 
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migration of other Th1 lymphocytes into the thyroid, which in turn, secrete more IFN-γ and 1 
TNF-α, stimulating further the chemokine production by the target cells, thus initiating and 2 
perpetuating the autoimmune cascade.  3 
To our knowledge, no study has evaluated systematically the IFN-γ inducible CXCL9 and 4 
CXCL11 chemokines in patients with GD in relation to thyroid function and treatment. The 5 
aim of the present study therefore was to measure serum CXCL9 and CXCL11 levels in 6 
patients with GD and to relate the findings to the clinical phenotype, in order to assess the 7 
potential benefit of routine assessment of these chemokines in the clinical management of 8 
such patients.  9 
 10 
Materials and Methods 11 
 12 
Patients  13 
From the outpatient clinic, we prospectively studied 91 consecutive Caucasian patients with 14 
GD, without clinical signs or symptoms of Graves’ ophthalmopathy (Table 1). The patients 15 
were referred to us by general practitioners or other hospitals because of the presence of 16 
hyperthyroidism or of circulating thyroid autoantibodies, or clinical suspicion of a thyroid 17 
disorder. The diagnosis of GD (14, 15) was established from the clinical presentation 18 
(presence of a diffuse goiter, varying in size from normal to very large), thyroid hormones 19 
and thyroid autoantibodies measurements [presence of antithyrotropin-receptor 20 
autoantibodies (TRAb), and/or thyroid ultrasonography (decreased, dyshomogeneous 21 
echogenicity, and diffuse goiter)]. The majority of these patients had goiter (61%), the others 22 
showed a normal thyroid volume. A minority of patients (7%) were submitted to fine-needle 23 
aspiration (FNA) of thyroid nodules to exclude the presence of thyroid cancer or lymphoma; 24 
in these cases, cytology excluded the presence of a malignancy.  25 
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Among the GD patients, 31 were untreated hyperthyroid patients (11 of them had a relapse of 1 
hyperthyroidism after a MMI course of 8-31 months), 50 were in treatment with MMI (2-34 2 
months duration), while the other 10 were euthyroid and in remission after a previous course 3 
of MMI therapy of 1-36 months duration.  4 
In terms of thyroid function, 48 were hyperthyroid [low TSH associated with high levels of 5 
free T3 (FT3) and/or free T4 (FT4)], 34 were euthyroid (normal TSH, FT3 and FT4), and 9 6 
were hypothyroid (high TSH, with normal or low levels of FT4 and/or FT3) while being 7 
treated with MMI.  8 
Controls 9 
We used two different controls to compare the features of GD not associated with 10 
hyperthyroidism (Comparison 1), or associated with hyperthyroidism (Comparison 2). The 11 
necessity to use two different comparisons was due to the fact that the mean age of GD 12 
patients was 41 years (Table 1), while the mean age of toxic nodular goiter (TNG) collected 13 
in the same period (used as control group of hyperthyroid GD) was 55 years; as serum 14 
CXCL10 levels are higher in older subjects (9), the Comparison 2 group was made excluding 15 
patients younger than 45 years in controls, with thyroiditis and GD, and with a matched age.  16 
Comparison 1  17 
Three control groups were used (Table 1). The first control group (controls I, n = 91) 18 
consisted of a random sample of the general population (matched by sex and age ± 2 years, 19 
with GD patients) from the same geographic area in whom a complete thyroid work-up 20 
[history, physical examination, TSH, FT3, FT4, antithyroglobulin (TgAb) and 21 
antithyroperoxidase (TPOAb) antibodies measurements, and ultrasonography] was available, 22 
and excluded the presence of thyroid disorders. 23 
A second control group was made by 91 patients with euthyroid chronic AT (matched by sex 24 
and age ± 2 years, with GD patients) (Table 1). The diagnosis of AT (22) was established 25 
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from the clinical presentation (presence of a firm goiter, varying in size from small to very 1 
large, with a lobulated surface), thyroid hormones and thyroid autoantibodies measurements, 2 
and/or thyroid ultrasonography (decreased, dyshomogeneous echogenicity).  3 
A third control group comprised 34 patients with non-toxic multinodular goiter (MNG) 4 
extracted from the same random sample of the general population (matched by sex and age ± 5 
2 years, with GD patients). The majority of these patients had a normal thyroid volume, some 6 
showed goiter (41%). All these patients were submitted to FNA to exclude the presence of 7 
thyroid cancer; cytology confirmed the absence of a malignancy.  8 
Comparison 2  9 
In the same period we collected the clinical history and the blood samples of 31 patients 10 
affected by TNG (diagnosed by thyroid scintigraphy) (Table 2). All patients were 11 
hyperthyroid, and the majority of them had a goiter (69%). All these patients were submitted 12 
to FNA to exclude the presence of thyroid cancer; cytology confirmed the absence of a 13 
malignancy. Owing to the fact that the mean age of the patients with TNG was 55 years and 14 
that serum CXCL9 levels are higher in older subjects the comparison 2 was made by 15 
matching TNG patients by age (± 3 years) and sex with controls, i.e. hyperthyroid patients 16 
with GD, or thyroiditis (Table 2). 17 
In all patients and controls, a blood sample was collected in the morning, after overnight 18 
fasting, and serum was kept frozen until thyroid hormones, TSH, thyroid autoantibodies, and 19 
CXCL9 and CXCL11 measurement. 20 
All study subjects gave their informed consent to participate in the study, which was 21 
approved by the local Ethical Committee.  22 
Ultrasonography of the neck and FNA  23 
Neck ultrasonography was performed by the same operator, who was unaware of the results 24 
of thyroid hormones, autoantibodies and CXCL10 measurements (Esaote, AU5 with a 25 
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sectorial 7.5 MHz transducer). Thyroid volume was calculated using the ellipsoid formula, as 1 
described (14, 15). The presence of hypoechoic and dyshomogeneous echogenicity was 2 
arbitrarily rated at three levels (0 = normal echogenicity; 1 = slightly hypoechoic and 3 
dyshomogeneous; 2 = severely hypoechoic and dyshomogeneous) in order to evaluate 4 
structural abnormalities of thyroid tissue associated with thyroid autoimmunity (14, 15). The 5 
presence of thyroid nodules was recorded, and nodules with a diameter >10 mm were 6 
submitted to ultrasonography-guided FNA, which was performed by the same operator, using 7 
a free-hand method as already described (14, 15).  8 
Thyroid blood flow (TBF) 9 
TBF by color-flow doppler (CFD) was studied in all patients (14, 15). The CFD pattern was 10 
defined as normal (or type 0): TBF limited to peripheral thyroid arteries; type I: TBF mildly 11 
increased; type II: TBF clearly increased; type III: TBF markedly increased (14, 15).  12 
Laboratory evaluation  13 
Thyroid function and thyroid autoantibodies were measured as previously described (22). 14 
Circulating FT3 and FT4 were measured by commercial RIA kits (AMERLEX-MAB FT3/ 15 
FT4 Kit; Amersham, UK). Serum TSH (DiaSorin, USA), TPOAb and TgAb (ICN 16 
Pharmaceuticals, USA) were evaluated by immunoradiometric assay (IRMA) methods. 17 
TRAb autoantibodies were measured with the use of a radioreceptor assay (Radim, Italy) 18 
(normal range 0-1 IU/mL). For TgAb, TPOAb, positivity was set at > 50, and > 10 IU/mL, 19 
respectively.  20 
Serum CXCL9, CXCL11, IFN-γ and CCL2 levels by ELISA  21 
Serum CXCL9 levels were assayed by a quantitative sandwich immunoassay using a 22 
commercially available kit (R&D Systems, Minneapolis, MN, USA), with a sensitivity 23 
ranging from 9-15.5 pg/mL and a mean minimum detectable dose of 5.6 pg/mL. The intra- 24 
and inter-assay coefficients of variation were 4.7% and 5.8%. 25 
 
 
                                                                 
 10 
Serum CXCL11 levels were assayed by a quantitative sandwich immunoassay using a 1 
commercially available kit (R&D Systems), with a sensitivity ranging from 2.1-4.5 pg/mL 2 
and a mean minimum detectable dose of 12.1 pg/mL. The intra- and inter-assay coefficients 3 
of variation were 4.9% and 6.8%.  4 
IFN-γ (Th1 cytokine) and CCL2 (Th2 chemokine) concentrations were also measured in 5 
serum using commercially available kits (R&D Systems). The mean minimum detectable 6 
level was 2.5 pg/mL for IFN-γ and 4.6 pg/mL for CCL2; the intra- and inter-assay 7 
coefficients of variation were 3.1% and 5.9% for IFN-γ, 4.3% and 5.2% for CCL2.  8 
Data analysis  9 
Values are given as mean ± SD for normally distributed variables, otherwise as median and 10 
interquartile range. Mean group values were compared by ANOVA for normally distributed 11 
variables, otherwise by the Mann-Whitney U or Kruskal-Wallis test. Proportions were 12 
compared by the χ2 test. Post-hoc comparisons of normally distributed variables were carried 13 
out using the Bonferroni-Dunn test. Multivariate analysis was performed by multiple linear 14 
regression analysis using CXCL9 or CXCL11 as dependent variable and age, TSH, FT3, as 15 
covariates. 16 
 17 
Results  18 
 19 
The demographic and clinical features of GD patients and controls are reported in Table 1. 20 
The mean CXCL9 levels were significantly higher in patients with GD, than in controls, or in 21 
patients with euthyroid AT or multinodular goiter (Fig. 1). 22 
In GD patients, serum CXCL9 levels were significantly higher in patients older than 50 years 23 
(p = 0.043, ANOVA), in GD patients with a hypoechoic pattern (55%) (p = 0.012, ANOVA), 24 
and in those with hypervascularity (68%) (p = 0.015, ANOVA) (Table 3), while no 25 
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significant difference was observed in relation to the presence of goiter, TPOAb, TgAb, or 1 
TRAb positivity. In a multiple linear regression model including age, TSH, and FT3, only age 2 
and FT3 were slightly but significantly related to serum CXCL9 levels (Table 4).  3 
Patients with GD and hyperthyroidism had significantly higher CXCL9 levels than euthyroid 4 
or hypothyroid GD patients (p = 0.01, ANOVA) (Fig. 2A), lower TSH (p < 0.001), and 5 
higher FT4 (p < 0.001), FT3 (p < 0.001), TRAb levels (p < 0.001), and higher degrees of 6 
hypervascularity (p = 0.001) (Table 5), while there was no significant difference in thyroid 7 
volume, echogenicity, TgAb and TPOAb titers.  8 
GD patients with untreated hyperthyroidism had higher CXCL9 levels than hyperthyroid 9 
patients treated with MMI, or euthyroid patients treated with MMI (p = 0.001, ANOVA) 10 
(Fig. 3A). CXCL9 levels were not significantly different in newly diagnosed untreated 11 
hyperthyroid patients in comparison with untreated patients with relapse of hyperthyroidism 12 
after a previous MMI course (Table 3). 13 
MMI-treated patients who were euthyroid had higher CXCL9 levels than patients in 14 
remission of  hyperthyroidism without treatment (p = 0.001, ANOVA) (Table 3).  15 
By defining a high CXCL9 level as a value of at least 2 SD above the mean value of the 16 
control group (> 142 pg/mL), 54% of patients with GD, 27% of AT, 3% of controls, and one 17 
of the MNG patients had high CXCL9 levels (p < 0.001, χ2) (Table 1). No relationship was 18 
observed between CXCL9 and disease duration.  19 
Patients with GD had higher levels of CXCL9 than patients with euthyroid AT, TNG, or age- 20 
and sex-matched controls (Table 2).  21 
The mean CXCL11 levels were significantly higher in patients with GD, than in controls or 22 
multinodular goiter patients (Table 1), and it was not significantly different from patients 23 
with euthyroid AT (Fig. 1B). 24 
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In GD patients, serum CXCL11 levels were significantly higher in GD patients with 1 
hypervascularity (p = 0.041, ANOVA) (Table 3), while no significant difference was 2 
observed in relation to the presence of goiter, TPOAb, TgAb, or TRAb positivity.  3 
Patients with GD and hyperthyroidism had significantly higher CXCL11 levels than 4 
euthyroid or hypothyroid GD patients (ANOVA, p = 0.03 respectively) (Fig. 2B).  5 
In a multiple linear regression model including TSH and FT3, they were not significantly 6 
related to serum CXCL11 levels. 7 
Patients with GD had significantly higher levels of CXCL11 than age- and sex-matched 8 
controls, while CXCL11 levels were higher, although not significantly, compared to 9 
euthyroid AT, or TNG (Table 2).  10 
GD patients with untreated hyperthyroidism had higher CXCL11 levels than hyperthyroid 11 
patients treated with MMI, or euthyroid patients treated with MMI (p = 0.006, ANOVA) 12 
(Fig. 3B). CXCL11 levels were not significantly different in newly diagnosed untreated 13 
hyperthyroid patients compared to untreated patients with relapse of hyperthyroidism after a 14 
previous MMI course (Table 3). 15 
Patients who were euthyroid while being treated with MMI or during remission of 16 
hyperthyroidism without treatment showed similar CXCL11 levels (Table 3). 17 
By defining a high CXCL11 level as a value of at least 2 SD above the mean value of the 18 
control group (> 104 pg/mL), 32 % of patients with GD, 27% of AT, 2% of controls, and one 19 
of the multinodular goiter patients had high CXCL11 levels (p < 0.001, χ2) (Table 1). No 20 
relationship was observed between CXCL11 and the GD disease duration. 21 
No significant relationship was observed between CXCL9 and CXCL11 serum levels in 22 
patients with GD, by simple regression. 23 
IFN-γ was detectable in the serum of 5% of controls, 6% of MNG, 45% of GD, and 37% of 24 
AT (p < 0.0001, χ2). IFN-γ levels were similar in GD (12 [5.2-25.4] pg/mL, median and 25 
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[interquartile range]), and in AT (10.1 [4.1-22.5] pg/mL) (p = ns).  1 
No significant relationship was observed between CXCL9, or CXCL11, or IFN-γ serum 2 
levels in patients with GD, by simple regression. 3 
CCL2 levels were similar in GD (403 [131-734] pg/mL, median and [interquartile range]), in 4 
AT (354 [154-673] pg/mL), MNG (339 [127-801] pg/mL) and controls (371 [143-724] 5 
pg/mL) (p = ns).  6 
 7 
Discussion 8 
 9 
The results of the present study confirm that CXCL9 and CXCL11 serum levels are increased 10 
in newly diagnosed patients with GD, and demonstrate a strong association with the 11 
hyperthyroid phase of the disease, with a decrease of both chemokines with MMI therapy. 12 
Furthermore, high levels of CXCL9 and CXCL11 were strongly associated with 13 
hypervascularity. The relapse of hyperthyroidism was characterized by CXCL9 and CXCL11 14 
serum levels similar to those observed in newly diagnosed hyperthyroid patients.  15 
Other studies suggest that a prevalent Th1 immune response is involved in AT, while a 16 
predominant Th2 response is associated with GD (23-26).  17 
Our results are in agreement with some studies that have shown a prevalent Th1 immune 18 
response in the initial phase of GD (8, 15). IFN-γ serum levels were higher in GD patients 19 
than in controls, confirming a Th1 involvement in GD and the results of previous studies (27-20 
29). 21 
The increase of CXCL9 in hyperthyroid patients with GD is in agreement with previous 22 
studies showing the involvement of IFN-γ (27), TNF-α (30) and Th1 cytokines in GD (27, 23 
31-35). Furthermore, the increase of serum CXCL9 in hyperthyroid patients with GD is in 24 
agreement with the results of another study that found that GD patients who relapsed or went 25 
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into remission had significantly different levels of CXCL9 (36).  1 
Moreover, it has been recently shown that IFN-γ and TNF-α are able to induce the secretion 2 
of the CXCL9 and CXCL11 chemokines in thyrocytes of patients with GD (11, 19-21).  3 
In our series, the increase of CXCL9 and CXCL11 seemed not associated with 4 
hyperthyroidism “per se”; in fact, the serum levels of these chemokines were higher in 5 
hyperthyroid Graves’ patients than in toxic nodular goiter. Therefore, the reported reduction 6 
of circulating CXCL9 and CXCL11 levels under MMI therapy could be reasonably ascribed 7 
to the well known immunomodulatory effect of antithyroid drugs (37, 38). This is also in 8 
agreement with the results observed for CXCL10 in GD patients treated with MMI (14, 15, 9 
34). 10 
Recently, it has been shown that MMI inhibits CXCL10 secretion in human thyrocytes. MMI 11 
decreased cytokine-induced CXCL10 secretion by reducing TNF-α-induced upregulation of 12 
the IFN-γ receptor (39).  13 
The site of production of CXCL9, CXCL10 and CXCL11 remains to be clarified. Cytokine 14 
production has been variably interpreted as sustained by thyroid follicular cells (TFC) (40), 15 
by intrathyroidal lymphocytes (27), or from the activation of humoral reactions in sites other 16 
than the thyroid (41, 42). However, the MMI-induced reduction of CXCL9 and CXCL11 17 
levels in our GD patients suggests that both intrathyroidal lymphocytes and TFC could be 18 
responsible for CXCL9 and  CXCL11 production. These findings are in agreement with the 19 
observed reduction of CXCL10 levels after 131I treatment, or thyroidectomy in GD patients, 20 
that suggests that the thyroid gland itself is the main source of circulating CXCL10 (43, 44). 21 
Patients with GD in remission after a previous course of MMI therapy show serum CXCL9 22 
and CXCL11 levels similar to normal controls or euthyroid multinodular goiters, but lower 23 
than patients with euthyroid AT. These data are in agreement with previous reports showing 24 
that CXCL10 expression was comparable to controls in patients with long-standing GD (8) 25 
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and suggest that CXCL9, CXCL10 and CXCL11 are transiently involved in the active phase 1 
of GD, when an active inflammatory process is present, and the Th1-mediated immune 2 
response is prevalent, while it is no more significantly present when remission of the disease 3 
is achieved. This finding may be regarded as a result of the negative feedback of Th2 4 
cytokines on IFN-γ production. This switch from a Th1 to a Th2 phenotype already reported 5 
in other long standing autoimmune diseases appears to be present also in GD, in line with a 6 
previous report showing that lymphocytes obtained from orbital and thyroid tissue of patients 7 
affected by Graves’ ophthalmopathy had a predominant Th1 profile, whereas patients with 8 
remote onset of hyperthyroidism had a large majority of Th2 lymphocytes (33). However, 9 
during relapse of hyperthyroidism, a new increase of CXCL10 is demonstrable, in line with a 10 
novel activation of the Th1-mediated immune response.  11 
The increase of CXCL9, CXCL10 and CXCL11 in the active phase of GD is in agreement 12 
with findings arisen from previous reports in which these chemokines have been 13 
contemporarily assessed in the serum and cerebrospinal fluid of multiple sclerosis patients 14 
(MS), showing significant modification in relation to the clinical phase of disease. 15 
Specifically, CXCL10 was higher in acute MS and lower in stable disease, suggesting a 16 
pathogenetic role for the chemokine in mediating clinical reexacerbation of MS (45). In 17 
addition, the previously reported inverse correlation between CXCL10 levels and time from 18 
last clinical relapse, together with the finding that CXCL9, CXCL10 and CXCL11 are 19 
upregulated during relapse in MS (46-48), strongly supports this hypothesis. 20 
The increase of CXCL9 and CXCL11 in patients with relapse of hyperthyroidism suggests 21 
that CXCL9 and CXCL11 could be used as prognostic markers in patients with GD after the 22 
remission of the hyperthyroidism with MMI treatment. Currently, this is typically addressed 23 
by the determination of TRAb, which represent the most useful addition to the clinical 24 
armamentarium and a low-cost assay in treatment planning; the major hurdle consists in 25 
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increasing the sensitivity of the available assays for TRAb in order to be applied successfully 1 
to a greater proportion of patients with GD (49). We have failed to show a relationship 2 
between the differences of CXCL9 or CXCL11 concentrations and the presence of circulating 3 
TRAb, TPOAb, or TgAb suggesting that the activation of the CXCL9 and CXCL11 system 4 
may be independent of autoantibody reactions in the thyroid.  5 
Interestingly, circulating levels of CXCL9 in GD patients were higher than those of CXCL11. 6 
This finding is in agreement with the results of previous studies that have shown that in 7 
primary cultures of thyrocytes, obtained from GD patients, the treatment with TNF-α plus 8 
IFN-γ has a significantly higher synergistic effect on CXCL9 secretion than on CXCL11 9 
release, and reinforces the hypothesis that the thyroid gland itself is the main source of these 10 
chemokines (19, 20). 11 
In conclusion, IFN-γ inducible chemokines CXCL9 and CXCL11 are associated with the 12 
active phase of GD both in newly diagnosed and in relapsing hyperthyroid patients. The 13 
reduction of circulating CXCL9 and CXCL11 levels in patients with GD treated with MMI 14 
may be related to the immunomodulatory effect of MMI. Future longitudinal studies in 15 
patients with GD will be necessary to assess the possible use of CXCL9 and CXCL11 serum 16 
levels as prognostic markers both in patients treated with MMI or after achievement of 17 
remission and as a possible addition to the TRAb assay. 18 
 19 
20 
 
 
                                                                 
 17 
Author Disclosure Statement 1 
The authors have no conflicts of interest to disclose. 2 
No competing financial interests exist. 3 
 4 
Corresponding author and person to whom reprint requests should be addressed: 5 
Alessandro Antonelli, MD 6 
Department of Clinical and Experimental Medicine 7 
University of Pisa 8 
Via Savi, 10, 56126, Pisa, Italy 9 
Phone: +39-050-992318 10 
Fax: +39-050-553235 11 
e-mail:  alessandro.antonelli@med.unipi.it 12 
13 
 
 
                                                                 
 18 
References  1 
 2 
1. Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P 2007 Role of chemokines in 3 
endocrine autoimmune diseases. Endocr Rev 28:492-520. 4 
2. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P 2003 Structure-function relationship 5 
between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289-295. 6 
3. Luster AD, Ravetch JV 1987 Biochemical characterization of a gamma interferon-7 
inducible cytokine (IP-10). J Exp Med 166:1084-1097. 8 
4. Farber JM 1997 Mig and IP-10: CXC chemokines that target lymphocytes. J Leukoc Biol 9 
61:246-257. 10 
5. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, 11 
Moser B, Wood DE, Sahagan BG, Neote K 1998 Interferon-inducible T cell alpha 12 
chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated 13 
T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009-2021.  14 
6. Colvin RA, Campanella GS, Sun J, Luster AD 2004 Intracellular domains of CXCR3 that 15 
mediate CXCL9, CXCL10, and CXCL11 function. J Biol Chem 279:30219-30227. 16 
7. Shimada A, Morimoto J, Kodama K, Suzuki R, Oikawa Y, Funae O, Kasuga A, Saruta T, 17 
Narumi S 2001 Elevated serum IP-10 levels observed in type 1 diabetes. Diabetes Care 24: 18 
510-515. 19 
8. Romagnani P, Rotondi M, Lazzeri E, Lasagni L, Francalanci M, Buonamano A, Milani S, 20 
Vitti P, Chiovato L, Tonacchera M, Bellastella A, Serio M 2002 Expression of IP-21 
10/CXCL10 and Mig/CXCL9 in the thyroid and increased serum levels of IP-10/CXCL10 in 22 
the serum of  patients with recent onset Graves’disease. Am J Pathol 161:195-206. 23 
 
 
                                                                 
 19 
9. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini 1 
E, Serio M 2004 High levels of circulating CXCL10 are associated with chronic autoimmune 2 
thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499. 3 
10. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Paolicchi A, Ferrannini E, 4 
Serio M 2005 Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta 5 
chemokine CCL2 serum levels in chronic autoimmune thyroiditis. Eur J Endocrinol 152:171-6 
177.  7 
11. García-López MA, Sancho D, Sánchez-Madrid F, Marazuela M 2001 Thyrocytes from 8 
autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ 9 
lymphocytes. J Clin Endocrinol Metab 86:5008-5016. 10 
12. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP 2003 11 
Detection and localization of chemokine gene expression in autoimmune thyroid disease. 12 
Clin Endocrinol (Oxf) 59:207-213.  13 
13. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, 14 
Uguccioni M, Galli G, Cosmi L, Maurenzig L, Baggiolini M, Maggi E, Romagnani S, Serio 15 
M 2001 Cell cycle dependent expression of CXC chemokine receptor 3 by endothelial cells 16 
mediates angiostatic activity. J Clin Invest 107:53-63.  17 
14. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Romagnani P, Grosso M, Ferrannini E, 18 
Serio M 2006 Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not 19 
associated with hyper- or hypothyroidism per se, but is specifically sustained by the 20 
autoimmune, inflammatory process. Eur J Endocrinol 154:651-658. 21 
15. Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Barani L, Ferrannini E, 22 
Serio M 2006 Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum 23 
levels in patients with active Graves' disease, and modulation by methimazole therapy. Clin 24 
Endocrinol (Oxf) 64:189-195.  25 
 
 
                                                                 
 20 
16. Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, 1 
Benvenga S, Paolicchi A, Ferrannini E, Fallahi P 2011 Circulating chemokine (CXC motif) 2 
ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in association 3 
with CXCL10. Cytokine 55:288-293. 4 
17. Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, 5 
Ferrannini E, Fallahi P 2011 Increase of circulating CXCL9 and CXCL11 associated with 6 
euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab 7 
96:1859-1863.  8 
18. Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, 9 
Miccoli P, Fallahi P 2012 High Levels of Circulating Chemokine (C-X-C motif) Ligand 11 10 
Are Associated with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis and 11 
with Chemokine (C-X-C Motif) Ligand 10. J Interferon Cytokine Res 32:74-80.  12 
19. Antonelli A, Ferrari SM, Frascerra S, Pupilli C, Mancusi C, Metelli MR, Orlando C, 13 
Ferrannini E, Fallahi P 2010 CXCL9 and CXCL11 chemokines modulation by peroxisome 14 
proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J 15 
Clin Endocrinol Metab 95:E413-E420. 16 
20. Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E 17 
2009 Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma 18 
inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and 19 
ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. 20 
J Clin Endocrinol Metab 94:1803-1809. 21 
21. Antonelli A, Ferrari SM, Frascerra S, Ruffilli I, Gelmini S, Minuto M, Pupilli C, Miccoli 22 
P, Sellari-Franceschini S, Ferrannini E, Fallahi P 2012 Peroxisome proliferator-activated 23 
receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy 24 
fibroblasts and preadipocytes. Mol Cell Endocrinol 349:255-261.  25 
 
 
                                                                 
 21 
22. Antonelli A, Fallahi P, Nesti C, Pupilli C, Marchetti P, Takasawa S, Okamoto H, 1 
Ferrannini E 2001 Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis 2 
or Graves' disease. Clin Exp Immunol 126:426-431.  3 
23. Qin Q, Liu P, Liu L, Wang R, Yan N, Yang J, Wang X, Pandey M, Zhang JA 2012 The 4 
increased but non-predominant expression of Th17- and Th1-specific cytokines in 5 
Hashimoto's thyroiditis but not in Graves' disease. Braz J Med Biol Res 45:1202-1208.  6 
24. Nanba T, Watanabe M, Inoue N, Iwatani Y 2009 Increases of the Th1/Th2 cell ratio in 7 
severe Hashimoto's disease and in the proportion of Th17 cells in intractable Graves' disease. 8 
Thyroid 19:495-501. 9 
25. McLachlan SM, Nagayama Y, Rapoport B 2005 Insight into Graves' hyperthyroidism 10 
from animal models. Endocr Rev 26:800-832. 11 
26. Phenekos C, Vryonidou A, Gritzapis AD, Baxevanis CN, Goula M, Papamichail M 2004 12 
Th1 and Th2 serum cytokine profiles characterize patients with Hashimoto's thyroiditis (Th1) 13 
and Graves' disease (Th2). Neuroimmunomodulation 11:209-213. 14 
27. Watson PF, Pickerill AP, Davies R, Weetman AP 1994 Analysis of cytokine gene 15 
expression in Graves' disease and multinodular goiter. J Clin Endocrinol Metab 79:355-360. 16 
28. Antonelli A, Rotondi M, Ferrari SM, Fallahi P, Romagnani P, Franceschini SS, Serio M, 17 
Ferrannini E 2006 Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in 18 
Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma 19 
agonists. J Clin Endocrinol Metab 91:614-620. 20 
29. Matsubayashi S, Kasuga Y, Sakatsume Y, Akasu F, Volpe R 1990 Serum interferon 21 
gamma levels in autoimmune thyroid disease. Clin Invest Med 13:271-274.  22 
30. Pichler R, Maschek W, Hatzl-Griesenhofer M, Huber H, Crespillo-Gómez C, Berg J 2003 23 
Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in 24 
thyrotoxic Graves' disease. Horm Metab Res 35:427-433. 25 
 
 
                                                                 
 22 
31. Miyauchi S, Matsuura B, Onji M 2000 Increased levels of serum interleukin-18 in 1 
Graves' disease. Thyroid 10:815-819.  2 
32. Siddiqi A, Monson JP, Wood DF, Besser GM, Burrin JM 1999 Serum cytokines in 3 
thyrotoxicosis. J Clin Endocrinol Metab 84:435-439. 4 
33. Mariotti S, Del Prete GF, Mastromauro C, De Carli M, Romagnani S, Ricci M, Pinchera 5 
A 1991 The autoimmune infiltrate of Basedow's disease: analysis of clonal level and 6 
comparison with Hashimoto's thyroiditis. Exp Clin Endocrinol 97:139-146. 7 
34. De Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, 8 
Del Prete G 1993 Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital 9 
lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 77:1120-1124. 10 
35. Aniszewski JP, Valyasevi RW, Bahn RS 2000 Relationship between disease duration and 11 
predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 12 
85:776-780.  13 
36. Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, Scherbaum 14 
WA, Schloot NC, Schott M 2008 Circulating chemokines in patients with autoimmune 15 
thyroid diseases. Horm Metab Res 40:416-421.  16 
37. Cooper DS 1984 Antithyroid drugs. N Engl J Med 311:1353-1362. 17 
38. Weetman AP, McGregor AM, Hall R 1984 Evidence for an effect of antithyroid drugs on 18 
the natural history of Graves' disease. Clin Endocrinol (Oxf) 21:163-172.  19 
39. Crescioli C, Cosmi L, Borgogni E, Santarlasci V, Gelmini S, Sottili M, Sarchielli E, 20 
Mazzinghi B, Francalanci M, Pezzatini A, Perigli G, Vannelli GB, Annunziato F, Serio M 21 
2007 Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes. J 22 
Endocrinol 195:145-155.  23 
40. Díez JJ, Hernanz A, Medina S, Bayón C, Iglesias P 2002 Serum concentrations of tumour 24 
necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with 25 
 
 
                                                                 
 23 
hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin 1 
Endocrinol (Oxf) 57:515-521. 2 
41. Salvi M, Pedrazzoni M, Girasole G, Giuliani N, Minelli R, Wall JR, Roti E 2000 Serum 3 
concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid 4 
function, ophthalmopathy and cigarette smoking. Eur J Endocrinol 143:197-202. 5 
42. Senturk T, Kozaci LD, Kok F, Kadikoylu G, Bolaman Z 2003 Proinflammatory cytokine 6 
levels in hyperthyroidism. Clin Invest Med 26:58-63.  7 
43. Antonelli A, Rotondi M, Fallahi P, Grosso M, Boni G, Ferrari SM, Romagnani P, Serio 8 
M, Mariani G, Ferrannini E 2007 Iodine-131 given for therapeutic purposes modulates 9 
differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients 10 
with active Graves' disease or toxic nodular goiter. J Clin Endocrinol Metab 92:1485-1490. 11 
44. Antonelli A, Fallahi P, Rotondi M, Ferrari SM, Serio M, Miccoli P 2006 Serum levels of 12 
the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' 13 
disease, and modulation by methimazole therapy and thyroidectomy. Br J Surg 93:1226-14 
1231.  15 
45. Sørensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA, Qin S, Rottman J, 16 
Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM 1999 Expression of specific 17 
chemokines and chemokine receptors in the central nervous system of multiple sclerosis 18 
patients. J Clin Invest 103:807-815.  19 
46. Mahad DJ, Howell SJ, Woodroofe MN 2002 Expression of chemokines in the CSF and 20 
correlation with clinical disease activity in patients with multiple sclerosis. J Neurol 21 
Neurosurg Psychiatry 72:498-502. 22 
47. Comini-Frota ER, Teixeira AL, Angelo JP, Andrade MV, Brum DG, Kaimen-Maciel DR, 23 
Foss NT, Donadi EA 2011 Evaluation of serum levels of chemokines during interferon-≤ 24 
 
 
                                                                 
 24 
treatment in multiple sclerosis patients: a 1-year, observational cohort study. CNS Drugs 1 
25:971-981. 2 
48. SzczuciDski A, Kalinowska A, Losy J 2007 CXCL11 (Interferon-inducible T-cell alpha 3 
chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated 4 
with methylprednisolone. Eur Neurol 58:228-232. 5 
49. Davies TF, Roti E, Braverman LE, DeGroot LJ 1998 Thyroid controversy--stimulating 6 
antibodies. J Clin Endocrinol Metab 83:3777-3785. 7 
8 
 
 
                                                                 
 25 
Table 1. Thyroid status of control subjects, or patients with autoimmune thyroiditis, or euthyroid 1 
multinodular goiter, or Graves' disease. 2 
 controls I thyroiditis multinodular Graves' p 
   goiter disease  
n 91 91 34 91  
      
Age (years) 43 ± 13 42 ± 12 43 ± 10 41 ± 11 ns 
      
Sex (M/F)% 23 23 24 23 ns 
      
Thyroid volume (mL) 10 ± 11 12 ± 13 19 ± 14 23 ± 16* < 0.001 
      
Hypoechoic (%) 0 65 0 55 < 0.001 
      
Hypervascular (%) 0 41 0 68 < 0.001 
      
Serum TSH (µU/mL) 1.4 ± 0.7 1.5 ± 1.1 1.0 ± 0.9 0.6 ± 1.7* 0.006  
      
TPOAb (IU/mL) 8 ± 11 456 ± 532° 10 ±6 342 ± 297° < 0.001 
      
TgAb (IU/mL) 7 ± 9 212 ± 284° 9 ± 11 164 ± 351° < 0.001 
      
TRAb (IU/mL) 0 0 0 25 ± 27§ < 0.001 
      
TPOAb positivity (%) 0 78 0 42 < 0.001 
      
TgAb positivity (%) 0 72 0 35 < 0.001 
      
CXCL9 (pg/mL) 76 ± 33 132 ± 78° 87 ± 48 274 ± 265§ < 0.001 
       
CXCL9 (> 142 pg/mL) 3% 27% 3% 54% < 0.001 
      
CXCL11 (pg/mL) 64 ± 20 108 ± 48^ 76 ± 33 140 ± 92°  0.009 
      
CXCL11 (> 104 pg/mL) 2% 27% 3% 32% < 0.001 
 3 
Antithyroperoxidase antibody=TPOAb; Antithyroglobulin antibody=TgAb; Antithyrotropin-receptor 4 
antibody=TRAb. Mean group values were compared by ANOVA for normally distributed variables, 5 
otherwise by Kruskal-Wallis test. Proportions were compared by the χ2 test. Post-hoc comparisons on 6 
normally distributed variables were carried out using the Bonferroni-Dunn test. 7 
* p < 0.05 or less vs. controls or vs. autoimmune thyroiditis. 8 
° p < 0.05 or less vs. controls and vs. multinodular goiters. 9 
^ p < 0.05 or less vs. controls. 10 
§ p < 0.05 or less vs. controls, vs. autoimumune thyroiditis and vs. multinodular goiters. 11 
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Table 2. Thyroid status of control subjects and patients with euthyroid autoimmune thyroiditis, or 1 
toxic nodular goiter, or Graves' disease.  2 
 controls thyroiditis toxic nodular Graves' p 
     goiter disease   
n 31 31 31 31  
      
Age (years) 57 ± 6 56 ± 10 55 ± 9 53 ± 10 ns 
      
Sex (M/F)% 29 29 29 29 ns 
      
Thyroid volume (mL) 11 ± 13 18 ± 16 31 ± 32° 27 ± 21° < 0.001 
      
Serum TSH (µU/mL) 1.7 ± 0.9 1.8 ± 1.2 0.03 ± 0.09° 0.02 ± 0.06° < 0.001 
      
TPOAb (IU/mL) 11 ± 7 453 ± 356* 9 ± 7 241 ± 276* < 0.001 
      
TgAb (IU/mL) 12 ± 9 542 ± 371* 10 ± 8 213 ± 275* < 0.001 
      
TRAb (IU/mL) 0 0 0 21 ± 19§ < 0.001 
      
CXCL9 (pg/mL) 88 ± 41 147 ± 91^ 112 ± 56  261 ± 283§  < 0.001 
            
CXCL11 (pg/mL) 67 ± 23 105 ± 52^ 91 ± 41  135 ± 79 ^ 0.012 
 3 
Antithyroperoxidase antibody=TPOAb; Antithyroglobulin antibody=TgAb; Antithyrotropin-receptor 4 
antibody=TRAb. Mean group values were compared by ANOVA for normally distributed variables, 5 
otherwise by Kruskal-Wallis test. Proportions were compared by the χ2 test. Post-hoc comparisons on 6 
normally distributed variables were carried out using the Bonferroni-Dunn test.  7 
° p < 0.05 or less vs. controls or vs. autoimmune thyroiditis. 8 
*p < 0.05 or less vs. controls and vs. toxic nodular goiter. 9 
^ p < 0.05 or less vs. controls. 10 
§ p < 0.05 or less vs. controls, vs. autoimumune thyroiditis and vs. toxic nodular goiter. 11 
12 
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Table 3. Serum CXCL9 and CXCL11 levels in relation to various parameters in patients with Graves’ 1 
disease. 2 
 3 
 4 
CXCL9  
Age   
> 50 years 
 
< 50 years p 
309 ± 243 pg/mL 216 ± 267 pg/mL 
 
0.043 
Hypoechoic pattern  
No 
 
Yes p 
209 ± 241 pg/mL 328 ± 284 pg/mL 
 
0.012 
Hypervascularity  
No 
 
Yes p 
234 ± 231 pg/mL 314 ± 301 pg/mL 
 
0.015 
Euthyroidism under MMI 
 
In remission of hyperthyroidism p 
191 ± 235 pg/mL 
 
122 ± 83 pg/mL 0.001 
Newly diagnosed untreated 
hyperthyroidism 
 
Untreated in relapse of 
hyperthyroidism 
p 
302 ± 295 pg/mL 
 
295 ± 308 pg/mL ns 
CXCL11  
Hypervascularity  
No 
 
Yes p 
111 ± 84 pg/mL 
 
160 ± 98 pg/mL 0.041 
Euthyroidism under MMI 
 
In remission of hyperthyroidism p 
101 ± 61 pg/mL 90 ± 44 pg/mL 
 
ns 
Newly diagnosed untreated 
hyperthyroidism 
 
Untreated in relapse of 
hyperthyroidism 
p 
168 ± 103 pg/mL 154 ± 87 pg/mL 
 
ns 
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Table 4. Multiple linear regression of CXCL9 vs. age, TSH, and FT3. 1 
 2 
 
 
 
 
standardized 
coefficient 
(β) 
 
regression 
coefficient 
(r.c.) 
 
CI (r.c.) 
95% lower 
 
 
CI (r.c.) 
95% upper 
 
p 
Age (years) 0.19 1.5 0.1 2.7 0.032 
TSH (ln[µU/mL]) -0.11 -1.2 -3.1 2.3 0.514 
FT3 (ng/L) 0.24 2.9 0.3 7.4 0.033 
Free T3=FT3; Confidence Interval=CI. 3 
4 
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 Table 5. CXCL9 serum levels in relation to thyroid status of patients with Graves’ disease.  1 
 2 
 GD 
hyperthyroidism  
GD 
euthyroidism 
GD 
hypothyroidism  
p 
CXCL9 (pg/mL) 340 ± 285 182 ± 175 195 ± 170 0.015 
TSH (µU/mL) 0.03 ± 0.07 0.65 ± 1.2 12.1 ± 17.4 < 0.001 
FT4 (pg/mL) 21.7 ± 12.4 9.3 ± 3.9 3.7 ± 2.5 < 0.001 
FT3 (µU/mL) 11.5 ± 7.4 3.9 ± 1.4 2.5 ± 0.8 < 0.001 
TRAb (IU/mL) 36 ± 31 17 ± 15 14 ± 12 < 0.001 
Degrees of 
hypervascularity (score 
units) 
1.1 ± 0.2 0.7 ± 0.3 0.3±0.4 
 
0.001 
 
 3 
4 
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Legends to Figures 1 
 2 
Figure 1. Distribution of serum CXCL9 (A), or CXCL11 (B), values in control subjects 3 
(Ctrl), in patients with autoimmune thyroiditis (AT), euthyroid multinodular goiter (MNG) 4 
and Graves’ disease (GD). The box indicates the lower and upper quartiles and the central 5 
line is the median value; the horizontal lines at the end of the vertical lines  are the 2.5% and 6 
97.5% values (* p < 0.05 or less vs. controls; ** p < 0.05 or less vs. controls, or vs. MNG; 7 
*** p < 0.05 or less vs. controls, or vs. AT, or vs. MNG; by Bonferroni-Dunn). 8 
 9 
Figure 2. Patients with Graves’ disease and hyperthyroidism (Hyper) had significantly higher 10 
CXCL9 (A), or CXCL11 (B) levels than euthyroid (Eu) or hypothyroid (Hypo) GD patients. 11 
The box indicates the lower and upper quartiles and the central line is the median value; the 12 
horizontal lines at the end of the vertical lines are the 2.5% and 97.5% values (* p < 0.05 or 13 
less vs. Eu, or Hypo; by Bonferroni-Dunn). 14 
 15 
Figure 3. Patients with Graves’ disease with untreated hyperthyroidism (Hyper) had higher 16 
CXCL9 (A), CXCL11 (B) levels than hyperthyroid patients treated with MMI (Hyper+MMI), 17 
or euthyroid patients treated with MMI (Eu+MMI) (* p < 0.05, by Bonferroni-Dunn). The 18 
box indicates the lower and upper quartiles and the central line is the median value; the 19 
horizontal lines at the end of the vertical lines are the 2.5% and 97.5% values. 20 
 21 
 22 
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